| Literature DB >> 30250996 |
Rahma Said1,2, Yoelsis Garcia-Mayea3, Nesrine Trabelsi1, Nouha Setti Boubaker1, Cristina Mir3, Ahlem Blel4, Nidhal Ati5, Rosanna Paciucci6, Javier Hernández-Losa3, Soumaya Rammeh4, Amine Derouiche5, Mohamed Chebil5, Matilde E LLeonart3,7, Slah Ouerhani8.
Abstract
Currently, microRNAs (miRs) represent great biomarkers in cancer due to their stability and their potential role in diagnosis, prognosis and therapy. This study aims to evaluate the expression levels of miRs-1260 and -1274a in prostate cancer (PC) samples and to identify their eventual targets by using bioinformatic analysis. In this project, we evaluated the expression status of miRs-1260 and -1274a in 86 PC patients and 19 controls by using real-time quantitative PCR and 2-ΔΔCt method. Moreover, we retrieved validated and predicted targets of miRs from several datasets by using the "multiMir" R/Bioconductor package. We have found that miRs-1260 and -1274a were over-expressed in PC patients compared to controls (p < 1 × 10-5). Moreover ROC curve for miRs-1260 and 1274a showed a good performance to distinguish between controls group and PC samples with an area under the ROC curve of 0.897 and 0.784 respectively. However, no significant association could be shown between these two miRs and clinical parameters such as PSA levels, Gleason score, tumor stage, D'Amico classification, lymph node metastasis statues, tumor recurrence, metastasis status and progression after a minimum of 5 years follow-up. Finally, a bioinformatic analysis revealed the association between these two miRs and several targets implicated in prostate cancer initiation pathways.Entities:
Keywords: Epigenetic; MiR-1260; MiR-1274a; Over-expression; Prostate cancer; Tunisia
Mesh:
Substances:
Year: 2018 PMID: 30250996 DOI: 10.1007/s11033-018-4399-x
Source DB: PubMed Journal: Mol Biol Rep ISSN: 0301-4851 Impact factor: 2.316